SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

🎯 Drug Targets

Browse 5 drug targets with druggability analysis, composite scores, and clinical context

5
Targets
0
High Druggability
0.51
Avg Score
15
Target Classes
Druggability Distribution
High: 0Medium: 5Low: 0Unknown: 0
Avg druggability score: 0.480
Clinical Pipeline
Approved: 1Phase III: 1Phase II: 3Phase I: 0Preclinical: 0
Total compounds: 16 · Approved: 3
Class All Classes Enzyme (35) Signaling Protein (25) Structural Protein (17) Protein (16) Gpcr (13) Ion Channel (12) Receptor (11) Transcription Factor (11) Ligand (10) Epigenetic Regulator (8) Transporter (8) Kinase (7) Other (4) Protease (4) Chaperone (4)
Druggability All Druggability Low (97) Medium (56) Undruggable (19) High (10) other (3)
Sort Score Druggability Gene A-Z Market Price
Filtered by: class=structural_protein, druggability=Medium — 5 results
SNCA Synuclein alpha Phase II
Structural Protein Medium Druggability
Score
0.60
Drug.
0.49
Safety
0.30
Drugs
2
Hyps
5
Papers
18
Immunotherapy targeting alpha-synuclein aggregates or small molecules preventing aggregation
TUBB3 Tubulin beta-3 chain Approved
Structural Protein Medium Druggability
Score
0.58
Drug.
0.49
Safety
0.30
Drugs
3
Hyps
1
Papers
32
Small molecule stabilizers of microtubule structure or assembly
STX17 Syntaxin-17 Phase II
Structural Protein Medium Druggability
Score
0.58
Drug.
0.46
Safety
0.30
Drugs
4
Hyps
2
Papers
28
STX17-targeting drugs would enhance or modulate autophagosome-lysosome fusion by facilitating SNARE complex assembly, thereby improving autophagic clearance of misfolded proteins and damaged organelles. This mechanism is particularly relevant for neurodegenerative diseases characterized by protein aggregation.
GFAP Glial fibrillary acidic protein Phase II
Structural Protein Medium Druggability
Score
0.41
Drug.
0.52
Safety
0.90
Drugs
3
Hyps
1
Papers
24
Biomarker readout — GFAP levels reflect astrocyte reactivity; modulating upstream pathways (e.g., NF-κB, JAK-STAT) reduces GFAP expression
MAPT Phase III
Structural Protein Medium Druggability
Score
0.36
Drug.
0.45
Safety
0.35
Drugs
4
Hyps
9
Papers
0
Tau aggregation inhibitors, anti-tau antibodies, tau phosphorylation modulators
Exchange | Dashboard